Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) reported dosing the first patient in ArMaDa3, its global, single Phase 3 registrational trial of OCU410, a one-time subretinal modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration. The 237‑patient, randomized 2:1 study compares OCU410 to an untreated control, using GA lesion growth rate by fundus autofluorescence as the primary endpoint and functional vision and ellipsoid zone preservation as key secondary endpoints.
According to Ocugen, the FDA granted RMAT designation to OCU410 on July 29, 2026, and aligned with a single, adequate and well‑controlled Phase 3 to support a planned BLA filing in 2028. Phase 2 12‑month data showed a statistically significant 31% reduction in GA lesion growth at the medium dose versus control and no OCU410‑related serious adverse events or adverse events of special interest.
Ocugen (NASDAQ: OCGN) will highlight its modifier gene therapy platform and clinical progress at three events in September 2026. The company is participating in the Citi 2026 Biopharma Back to School Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, both as fireside chats featuring Chairman and CEO Dr. Shankar Musunuri. On September 24, Ocugen will present 12‑month randomized Phase 2 ArMaDa results for subretinal OCU410 gene therapy in geographic atrophy at The Retina Society 59th Annual Scientific Meeting, presented by Dr. Raj K. Maturi. Webcasts of the Citi and H.C. Wainwright sessions will be accessible via the Investors section of Ocugen’s website, with replays available for 30 days.
Ocugen (NASDAQ: OCGN) reported second quarter 2026 results and a broad business update. FDA cleared the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy, based on 12‑month Phase 2 data showing a statistically significant 31% reduction in lesion growth at the planned Phase 3 dose, and granted RMAT designation, with BLA/MAA filings targeted for 2028.
Enrollment was completed in pivotal trials of OCU400 for retinitis pigmentosa (N=140) and OCU410ST for Stargardt disease (N=63), with topline data expected in 1Q and 2Q 2027, respectively. Ocugen signed a binding term sheet with Roots Pharmaceutical and Al‑Dhow International Holding for an exclusive OCU400 license in MENA, including up to $255 million in sales milestones and a 22% royalty on net sales.
The company closed a $130.0 million 6.75% convertible senior notes offering (net proceeds ~$112.5 million), using ~$32.7 million to fully retire higher‑cost Avenue Capital debt, and extending its cash runway into 2028. As of June 30, 2026, cash and restricted cash were $100.4 million, revenue was $1.5 million, operating expenses were $17.9 million, and net loss was $24.9 million, or $0.07 per share.
Ocugen (NASDAQ: OCGN) will participate in two August 2026 investor events focused on its modifier gene therapy platform for blindness diseases. The company will join a panel at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4 in Lenox, MA, and host a fireside chat at the Canaccord 46th Annual Growth Conference on August 11 in Boston, MA. A live webcast and 30-day replay of the Canaccord session will be available via the Investors section of Ocugen’s website.
Ocugen (NASDAQ: OCGN) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational gene therapy OCU410 for treating geographic atrophy (GA) secondary to dry age-related macular degeneration.
According to Ocugen, the RMAT designation, based on Phase 2 data showing clinically meaningful efficacy and a favorable safety profile with no serious drug-related adverse events reported, may enable an expedited regulatory path. The company recently aligned with the FDA on the design of a Phase 3 registrational trial, which it expects to initiate in the third quarter of 2026, and anticipates filing a Biologics License Application (BLA) in 2028.
Ocugen (NASDAQ: OCGN) announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 6, 2026 to discuss its second quarter 2026 financial results and provide a business update. A pre-market earnings announcement will be issued the same day.
According to Ocugen, U.S. participants can dial (800) 715-9871 and international participants can dial (646) 307-1963, using Conference ID: 2222566. A live and archived webcast, as well as a replay of the call, will be available in the events section of the Ocugen investor website.
Ocugen (NASDAQ: OCGN) signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, a modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa (MENA) region.
According to Ocugen, the anticipated license agreement would provide up to $4 million in upfront and near-term development milestone payments, cumulative sales milestones up to $255 million, and a 22% royalty on net sales generated by its partner. Ocugen would also manufacture commercial supply of OCU400 under a related supply agreement. The company continues to advance OCU400 in its Phase 3 liMeliGhT trial, with topline data expected in 1Q 2027 followed by a planned BLA submission. Execution of the definitive agreement is expected within 90 days.
Ocugen (NASDAQ:OCGN) will participate in several ophthalmology-focused conferences in July 2026, highlighting its modifier gene therapy platform and retinal disease programs.
Events include Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS presentations featuring OCU410 Phase 2 ArMaDa 1-year results and Phase 1/2 safety and imaging analyses.
Ocugen (NASDAQ: OCGN) will present its modifier gene therapy platform and retinal disease innovation at multiple June 2026 investor and industry conferences.
Events include the Noble Capital Markets Emerging Growth Virtual Equity Conference, Clinical Trials at the Summit 2026, and the BIO International Convention, with webcast access for Noble.
Ocugen (NASDAQ: OCGN) closed a private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 to qualified institutional buyers under Rule 144A, including a $15.0 million over-allotment option.
The notes were priced at 90% of principal, generating approximately $112.6 million in net proceeds. Ocugen used about $32.7 million to fully repay its Avenue Capital loan, including interest and fees, and plans to use the remaining proceeds for general corporate purposes. According to Ocugen, this financing extends its anticipated cash runway into 2028 to support three late-stage programs and the goal of filing three BLAs by 2028.